$1,318.00
This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals.
This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient subtypes
9 Symptoms
9 Risk factors
9 Diagnosis
10 TREATMENT
10 Anti-TB drugs
11 Surgery
12 EPIDEMIOLOGY
17 MARKETED DRUGS
19 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 Pretomanid for TB (June 6, 2019)
26 Pretomanid for TB (June 4, 2019)
28 Pretomanid for TB (April 18, 2019)
30 KEY UPCOMING EVENTS
31 KEY REGULATORY EVENTS
31 The FDA’s Latest Nitrosamine Decision Weighs Tuberculosis Versus Cancer Risk
31 Hope For Price Flexibility After India Pretomanid Go-Ahead
31 Pediatric Approvals In TB, Bladder Dysfunction, And Atopic Dermatitis
31 Mylan Gets Expert Panel Go-Ahead For Pretomanid In India
31 Global Approvals Snapshot: November 2019
33 PROBABILITY OF SUCCESS
34 LICENSING AND ASSET ACQUISITION DEALS
34 Pfizer Deal Covers Sutezolid For TB
34 Deals Shaping The Medical Industry, December 2019
34 Shionogi, Hsiri Expand Mycobacterial R&D Pact
35 CLINICAL TRIAL LANDSCAPE
36 Sponsors by status
37 Sponsors by phase
38 Recent events
39 BIBLIOGRAPHY
39 Prescription information
40 APPENDIX
LIST OF FIGURES
14 Figure 1: Global trends in incident cases of tuberculosis, 2018–27
19 Figure 2: Overview of pipeline drugs for tuberculosis in the US
19 Figure 3: Pipeline drugs for tuberculosis, by company
20 Figure 4: Pipeline drugs for tuberculosis, by drug type
20 Figure 5: Pipeline drugs for tuberculosis, by classification
30 Figure 6: Key upcoming events in tuberculosis
33 Figure 7: Probability of success in the antibacterial, mycobacterial, or fungal pipeline
35 Figure 8: Clinical trials in tuberculosis
35 Figure 9: Top 10 drugs for clinical trials in tuberculosis
36 Figure 10: Top 10 companies for clinical trials in tuberculosis
36 Figure 11: Trial locations in tuberculosis
37 Figure 12: Tuberculosis trials status
38 Figure 13: Tuberculosis trials sponsors, by phase
LIST OF TABLES
13 Table 1: Global incident cases of tuberculosis, 2018–27
15 Table 2: Global incident cases of tuberculosis with HIV, 2018
16 Table 3: Global incident cases of MDR/RR tuberculosis, 2018
18 Table 4: Marketed drugs for tuberculosis
21 Table 5: Pipeline drugs for tuberculosis in the US
24 Table 6: Pretomanid for TB (June 6, 2019)
27 Table 7: Pretomanid for TB (June 4, 2019)
28 Table 8: Pretomanid for TB (April 18, 2019)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!